We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Testing Can Identify Patients with Inherited Risk of Cardiomyopathy

By LabMedica International staff writers
Posted on 22 Nov 2023

Cardiomyopathy, a diverse heart condition, impairs the heart's pumping efficiency by causing the muscles to stiffen, enlarge, or weaken. More...

This can result in various complications, including irregular heartbeat, heart attacks, and potentially fatal outcomes. While some cardiomyopathy cases are acquired due to conditions like muscular dystrophy or alcoholism, approximately half are inherited genetically. Now, new research indicates that genetic screening is a valuable tool for identifying patients with cardiomyopathy, enhancing their life quality, and reducing mortality risks.

A comprehensive study by Intermountain Health (Salt Lake City, UT, USA) involving over 30,000 heart patients revealed the effectiveness of genetic screening in identifying those with this serious heart condition. This process enables clinicians to monitor these patients more closely and intervene medically when needed, potentially improving their quality of life and even saving lives. The study is a part of the HerediGene: Population Study, the most extensive DNA mapping project globally. The initiative aims to uncover new connections between genetics and various diseases.

Additionally, the study offers genetic screenings to participants to inform them about their disease risks and proactive health measures. The screening specifically identifies the pathogenic TTN variant, which impacts the gene responsible for producing a protein in cardiac muscles. Analysis of the first 32,159 sequenced patients revealed 411 with a pathogenic/likely pathogenic TTN variant. Of these, 135 (32.8%) had a cardiomyopathy diagnosis, while 276 (67.2%) did not. Interestingly, about a third of those with a potentially pathogenic TTN variant were diagnosed with cardiomyopathy; 27% showed no diagnosis but had indications of the disease.

Demographic and clinical characteristics varied significantly between those with and without a cardiomyopathy diagnosis. Among those undiagnosed, 75 (27%) showed clinical signs of cardiomyopathy. Of this group, 12 (16%) had passed away, and 22 (23%) had been hospitalized for heart failure. These findings underscore the need for more widespread whole genome testing. The researchers suggest regular monitoring of individuals with the genetic variant through echocardiograms from an early age and immediate attention upon exhibiting disease symptoms, adhering to standard cardiomyopathy care protocols.

“Our findings show that we’re missing a large percentage of the population that’s walking around with a genetic predisposition to a devastating kind of heart disease,” said Kirk Knowlton, MD, lead author of the study and director of cardiovascular research at Intermountain Medical Center. “Widespread genetic testing can identify these patients, and their families, which means we can better treat them.”

Related Links:
Intermountain Health 


New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.